CEVEC Appoints New Management Team

Cologne, Germany, September 19, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed Chief Business Officer and Frank Ubags joins as Chief Operating Officer.

“Our vision is to become the leading independent player for human cell line based clinical materials. This management team possesses all skills, competencies and experience to achieve this ambitious target."
"I am very pleased to welcome Frank Ubags to our team. Frank has an outstanding track record in the biopharmaceutical sector in establishing and implementing growth strategies. Together with him we have now accomplished a strong management team to lead CEVEC through its next stage of corporate growth” stated Wolfgang Kintzel, CEO at CEVEC.

Wolfgang Kintzel, Chief Executive Officer, biologist by training (MSc) joined Schering/Berlex gaining quickly more responsibility in various sales and marketing functions. With now more than 18 years of experience in different roles within the pharmaceutical, medical device and biotech industry in leading European and US based organizations he had full P&L responsibility up to 100 Mio €. Wolfgang managed organizations up to 170 employees. From 2000 - 2008 he built up amaxa AG as global VP Marketing & Sales from a true start-up situation to a fully integrated company complemented with an outstanding M&A experience in 2008 when the company was sold to Lonza Group Ltd., Switzerland. Wolfgang joined CEVEC in 2009 as Managing Director. Wolfgang holds several board assignments in European biotech companies
Frank Ubags, Chief Operating Officer, has more than 35 years of business experience in renowned companies. He joined the life science business in 1997 as CFO of Rhein Biotech. He led the IPO at the Neuer Markt in 1999 and initiated and executed the transformation of Rhein Biotech into a vaccines company through a major acquisition, 2 years later followed by a sale to Berna Biotech. Frank served from 2004 as CEO of the German Rhein Biotech operation and after its sale to Dynavax, he joined Kiadis Pharma in 2006 as CFO. In 2009 he joined Scil Proteins as CFO. After a successful financing round in 2011, he took over in 2012 the COO position for the Scil Proteins CMO operation where he led the company through a successful FDA inspection and he initiated the sale of Scil Proteins Production to Wacker Biotech. Frank holds several advisory positions in the field of protein production.
Dr. Nicole Faust, Chief Scientific Officer, holds a Ph.D. in Molecular and Cell Biology. After a post-doctoral period at the EMBL, Heidelberg, she joined Artemis-Pharmaceuticals GmbH, Cologne in 1999 where she took over responsibility for the Molecular Technology group as Associate Director R&D. In 2004 she started a position with amaxa GmbH, now Lonza Cologne GmbH. As Director R&D she was responsible for developing transfection technologies, for the cell-based assay program, and for establishing and running the cell line development services. She joined CEVEC in May 2011 as VP Development & Services and was appointed Chief Scientific Officer in 2014.
Dr. Hartmut Tintrup, Chief Business Officer, served previously as VP Business Development & Licensing at CEVEC and holds a Ph.D. in Neurochemistry from Frankfurt University, Germany. He spent 16 years in various positions of increasing responsibility at leading Biotech Companies in the US and Germany. Prior to joining CEVEC he held management positions at amaxa AG and Lonza in Industrial Sales and Tactical Marketing. Hartmut joined CEVEC in 2010 was appointed Chief Business Officer in 2014.

About CEVEC Pharmaceuticals GmbH - www.cevec.com
CEVEC offers the human amniocyte-based protein expression platform CAP for the transient and stable production of superior Biopharmaceuticals, CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines.

Contact
Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Straße 62
D-51105 Germany
Fon +49 (0) 221 46020800
Fax +49 (0) 221 46020801
info@cevec.com

Vibalogics GmbH Licenses CAP Technology from Cevec

Cologne, Germany, January 27th 2014
CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes (CAP Cells), and Vibalogics GmbH, international manufacturer of viruses and bacteria for novel biological products announced a collaboration in the field of virus production and vaccine development today,

where Vibalogics has licensed CEVEC’s CAP and CAP-T Cell Expression Systems as a tool to produce various cell derived viral products. The agreement allows Vibalogics to evaluate CAP technology on behalf of its clients to determine the potential advantages of CAP cells in head-to-head studies with other cell line candidates.
The agreement also enables Vibalogics to produce viruses for pre-clinical studies ahead of subsequent contract manufacturing of clinical material under GMP conditions.
CAP and CAP-T Cells are immortalized suspension cells developed by CEVEC initially for recombinant protein production. Adapted to serum-free growth conditions the cells are optimized to grow in a variety of flask/Wave formats and large-scale bioreactors.
These non-tumor origin cell lines exhibit a broad susceptibility for various human pathogenic viruses and are an excellent tool for vaccine and virus production.
“We are very pleased to be working with Vibalogics, a leading expert in virus manufacturing and a capable partner for companies wishing to employ CAP Technology during the product development phase”

said Wolfgang Kintzel, CEVEC’s CEO.
“With the increasing demand we have recently observed for our CAP cells as an efficient viral production system we’re glad to recommend Vibalogics as an expert to develop CAP derived viral products from feasibility studies up to larger scale GMP manufacture.”
Stefan Beyer, Managing Director of Vibalogics commented
“As an established GMP manufacturer for companies with viral candidates for clinical trials, we are always looking for opportunities to add value to our clients. By collaborating with CEVEC and offering the CAP Technology, we are able to offer a proven alternative cell substrate for virus production that could potentially offer our clients significant benefits over other cell lines"

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP and CAP-T Expression Systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.
Visit www.vibalogics.com to find out more.

Completion of a “First in Human” clinical Phase I study using CAP Cells

Cologne, Germany, November 1st, 2013

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes (CAP Cells), announced today that a Dutch consortium led by TNO reported the safe completion of a clinical Phase I study with recombinant human Alkaline Phosphatase (hRESCAP) derived from CEVEC’s CAP Cells.

The consortium consisting of TNO and Alloksys Life Sciences B.V., among others, performed a dose escalating investigative Phase I study to determine the safety and pharmacokinetics of parenterally delivered hRESCAP in healthy volunteers.
Paving the path to ultimately treat chronic inflammatory diseases like Rheumatoid Arthritis in AMRIF B.V., a recently founded sister company to Alloksys Life Sciences, the study represents a major milestone for CEVEC since it establishes the CAP Cell Line as a regulatory-proven expression host for the broader production of therapeutic proteins, antibodies and vaccines.

CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior yields of complex (glyco) proteins in a shorter time frame than traditional methods.

“We’re proud that our long-standing collaboration with Alloksys Life Sciences B.V. to produce recombinant human alkaline phosphatase at high yields and consistent quality in CAP has  succeeded to enter the clinic. The safe and very promising outcome of this study underlines the potential of our human CAP Cells to become a standard expression host for therapeutic and clinically relevant proteins. TNO obtained regulatory approval to conduct a single ascending dose study with hRESCAP produced with CEVECs expression system. This will certainly facilitate the regulatory acceptance and pave the way for clinical development  of all other CAP-derived therapeutics that are currently at preclinical stage or entering clinical development“ stated Wolfgang Kintzel, CEO at CEVEC.


About CEVEC Pharmaceuticals GmbH - www.cevec.com- 

CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP and CAP-T Expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.


About Alloksys Life Sciences B.V.  - www.alloksys.com-

Alloksys Life Sciences (www.alloksys.com) is a bio-pharmaceutical company, focusing to the development of RESCAP for the short term and long-term prevention and treatment of ischemia- and hypoxia mediated (inflammatory) injury and its complications, such as occurring peri-and post surgically.  Currently bovine derived RESCAP has progressed to clinical phase 3a in patients undergoing invasive cardiac valve surgery. Development of recombinant human RESCAP was initiated by Alloksys under a European Trans Bio program together with CEVEC Pharma (Germany) and in cooperation with Ibet/GenIbet (Portugal) and AgentschapNL , and is now transferred to a sister biotech company (AMRIF B.V.) for application in chronic diseases.


About AMRIF B.V. - www.alloksys.com-

AMRIF was founded in June 2013 and is a bio-pharmaceutical company, focusing its R&D programs on the development of the RESCAP platform technology on innovative targets and therapies towards the treatment of patients debilitating chronic diseases.  According to AMRIF this phase I study is a first step towards programs that gain access to the development of RESCAP as compound fulfilling unmet medical needs.


About TNO   -www.tno.nl-

The 3800 TNO professionals put their knowledge and experience to work in creating smart solutions to complex issues. These innovations help to sustainably strengthen industrial competitiveness and social wellbeing. We are partnered by some 3000 companies and organisations, including SMEs, in the Netherlands and around the world.

 

Contact:


Wolfgang Kintzel, CEO

CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
phone +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com

CEVEC Pharmaceuticals founds HCMV vaccine spin-out

Cologne, Germany, September 15th, 2013/ 

CAP-CMV Gmbh is a spin-out of CEVEC Pharmaceuticals GmbH (CEVEC) and focuses exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection.

The approach of CAP-CMV is the use of non-infectious “HCMV dense bodies (DB)”, which is one of the most convincing technology approaches to date. The novel vaccine can be produced in industrial scale using a serum free, suspension culture environment. The novel dense body based vaccine (CAP-CMV-001) as well as the CAP® cell line is protected by a strong patent portfolio. For further information regarding this  unique investment opportunity, please contact


Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com

 

Clinical Development of a Novel Human Cytomegalovirus Vaccine

Cologne, Germany, January 3, 2013 / B3C newswire / - CEVEC Pharmaceuticals, the developer of the CAP® Technology, a novel human expression system derived from amniocytes, and VPM – Vakzine Projekt Management GmbH, announced today the signing of an exclusive license agreement on VPM’s proprietary human CMV dense body technology.


CAP® Technology is based on an immortalized human cell line for vaccine and protein production developed by CEVEC for industrial use. The serum-free suspension culture of this proprietary cell line allows for high virus yields for a broad variety of human pathogenic viruses. CAP® cells are uniquely suited to produce vaccines against challenging viral targets like human CMV. The non-infectious dense bodies are considered to be one of the most promising new CMV vaccine approaches since they result in efficient and long-lasting immunity. The CMV dense body project is foreseen to enter clinical development within the next 18 months. CEVEC receives exclusive word-wide development and commercialization rights from VPM and VPM will substantially contribute by taking over development project management services for the project. The inventor of the CMV dense body technology, Prof. Dr. Plachter, an internationally reputed CMV expert, actively supports in the project as leading scientific expert.


“With VPM we are teaming up with a very reputed development partner in the field of state-of-the art vaccines for current high-medical need diseases like human CMV. We’re very pleased that VPM and CEVEC are combining our CAP® suspension cells as the enabling production platform with VPMs unique dense body technology. I’m convinced that the dense body technology and CAP® are a perfect match and the combined efforts will substantially shorten the timeline to enter clinical phases,“ stated Wolfgang Kintzel, CEO at CEVEC. "This project shows a scientific and commercial potential untapped in the field of currently pursued viral vaccine targets, " Dr. Rainer Lichtenberger, CFO/COO at CEVEC complements.


“It is a great success story in translational research for VPM and Helmholtz Centre for Infection Research that we were able to bring this early stage vaccine project from academia to industry. With the out-licensing of the CMV dense body project to CEVEC, VPM could again demonstrate that its translational business model is instrumental in developing promising vaccine candidates to a stage of maturity where they can envisage a full pharma development. Cooperating with Cevec will help this potentially live-saving vaccine to tap its full potential”, added Dr. Bernd Eisele CEO of VPM.

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-TTM expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies and is developing the CAP technology as a superior production platform to enable difficult to produce viral targets.


About VPM – Vakzine Projekt Management GmbH
VPM was founded in 2002 from Helmholtz-Center for Infection Research. VPM has been active in developing promising biopharmaceutical candidates from academic research. Several products, ranging from small molecules, recombinant proteins up to live vaccines and ATMPs, have successfully been brought into clinical phase I and II trials by VPM and its team members. VPM now offers its experience in translational project management and regulatory liason to its clients in Pharma, Biotech, and Academia. VPM moves developmental products to the clinical stage faster, more cost-efficiently, and with higher success rates.

Contacts:
Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com


Bernd Eisele, MD, CEO
Vakzine Projekt Management GmbH
Mellendorfer Straße 9
D-30625 Hannover, Germany
fon: +49 511 1699080
fax: +49 511 16990829
info@vakzine-manager.de
www.vakzine-manager.de

CEVEC Signs License Agreement with Yuhan Corporation of South Korea

Cologne, Germany, December 20, 2012 / B3C newswire / - CEVEC, the developer of a novel human expression system derived from amniocytes, and Yuhan, a leading manufacturer of pharmaceutical products based in Seoul, Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.

CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.

“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases “ stated Wolfgang Kintzel, CEO at CEVEC.

Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of CEVEC’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules"

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Yuhan
Yuhan Corporation, the leading pharmaceutical company in South Korea, is focusing its R&D capabilities on new chemical entities, new biologics, herbal medicines, and APIs for global markets. For the last 86 years, Yuhan is committed to deliver advanced and innovative medicines with a slogan “Innovative, Nimble, and Translational R&D”. In 2007, ‘Revanex’, the world’s first acid pump agonist was out-licensing to China, and is now supplied world-wide to markets in Asia. Yuhan is to become the global premiere customer-focused pharma company with value driven, globally competitive R&D capability.

Contact

Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com

Jong-Gyun Kim, Ph.D.
Head, BioInnovation Unit, Yuhan Corporation
416-1 Gongse-dong, Yongin-si, Korea
Tel +82 31-899-4168
Fax +82 31-275-6145
myseed@yuhan.co.kr

Join Us for a Max Cyte Webinar on Wed, Dec 12, 2012 11:00am - 12:00pm EST

MaxCyte Transient Transfection of Biologically Relevant Cells: CEVEC CAP-T Technology for High Yield Expression of Proteins in Human-Derived Cells

Register Now (by clicking here) !

Learn how to produce proteins with authentic human post-translational modifications using MaxCyte flow electroporation for large scale, transient transfection.

Overview:
Changes in post translational modifications can affect the therapeutic potential of biotherapeutics under development. Thus it is important to produce and evaluate antibodies and proteins of interest with human post translational modifications early in the biotherapeutic development pipeline. The MaxCyte STX Scalable Transfection System allows for fully scalable transient transfection of human-derived cells, such as CEVEC's CAP-T cells, for production of recombinant proteins and antibodies with authentic human post translational modifications. CEVEC has developed an expression system for biopharmaceuticals based on human amniocytes offering significant advantages over existing production technologies.

Register now (by clicking here) for this webinar to learn how using MaxCyte large scale transient transfection of CAP-T cells allows for:

• Can transfect from 5E5 cells in seconds to 2E11 cells in
  <30 minutes
• High yields of authentic complex proteins reducing costs
  of downstream processing
• Increased specific activity of therapeutics, thereby reducing
  protein dose
• Avoidance of immunogenic non-human carbohydrate residues
• Authentic sialylation of therapeutics for improved half-lives

Discussions lead by:

Dr. Hartmut Tintrup
VP Business Development & Licensing, CEVEC Pharmaceuticals 

James Brady, Ph.D.
Director, Technical Applications, MaxCyte, Inc. 

Karen Donato, Ph.D.
EVP, Global Business Development & Marketing, MaxCyte, Inc.

MaxCyte, Inc.
22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
(301) 944-1700
info@maxcyte.com
www.maxcyte.com

CATALENT ANNOUNCES CELL LINE SALES AGREEMENT WITH CEVEC

Deal follows study which achieved record yield for human alpha-1 antitrypsin (hAAT) molecule 

Somerset, NJ, November 13, 2012 – Catalent Pharma Solutions today announced that it had reached a commercial cell line sales agreement with CEVEC Pharmaceuticals for recombinant human alpha-1 antitrypsin (hAAT).

The companies have also signed a  joint development and marketing agreement that combines CEVEC’s CAP® cell line, a high performance protein expression platform originally derived from primary human amniocytes and Catalent‘s GPEx® technology, a powerful gene-insertion method providing single-copy gene integration at multiple genomic locations in dividing cells. This agreement will allow the co-promotion of the combined technologies to biotechnology companies needing cell line development and manufacturing of various proteins.

The announcements follow a successful five month study which achieved a new milestone in the field of complex protein production, having demonstrated a record yield for a non-antibody protein produced in a human expression system.

Leading global drug development and delivery solution provider Catalent, and CEVEC, the developer of a novel, market-leading human protein expression system derived from amniocytes, achieved a manufacturing yield of over 3 grams per liter for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative  proprietary technologies. The program began with the development of a GPEx based stable pool in CAP cells at Catalent, followed by initial process development at CEVEC.

“Enabling biotech companies to get clone candidates to clinic more quickly and efficiently is at the core of Catalent’s biologics business philosophy,” commented Kent Payne, Vice President and General Manager, of Catalent’s Biologics business. “Having developed the hAAT molecule using our combined technologies, we have now reached a commercial agreement with CEVEC on the cell line and look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

“We are very excited to have proven the potential for generating high expressing human cell lines in a much shorter timeframe than traditional methods,” added Wolfgang Kintzel, CEO of CEVEC. “As the yield of 3 g/L was achieved already at the stable pool stage, a further increase in productivity is expected by the ongoing generation of the clonal cell line. The high yield attained for a difficult to express and therapeutically relevant protein, such as hAAT, represents an enabling milestone for large scale manufacturing of complex proteins in human cells.”

About Catalent
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T T expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.
For more information, visit www.cevec.com.

Christopher Halling
Strategic Marketing Manager - Europe
Catalent Pharma Solutions
Frankland Road, Blagrove, Swindon, Wiltshire, UK - SN5 8YG
M +44 (0)7580 041073
www.catalent.com
more products. better treatments. reliably supplied.™

Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Strasse 62
D-51105 Cologne, Germany
T +49 (0) 221-46 02 08 00
info@cevec.com
www.cevec.com

CCS Cell Culture Service Signs Strategic License Agreement with CEVEC

Cologne and Hamburg, Germany, November 5, 2012 / B3C Newswire / - CEVEC Pharmaceuticals ("CEVEC"), the developer of a novel human expression system derived from amniocytes, and CCS Cell Culture Service GmbH ("CCS"), a contract research organization based in Hamburg, Germany, announced today the signing of a strategic license agreement.

The license will enable CCS to offer its customers transiently transfected CAP-TTM cells for cell based assay and protein production applications.


The transient CAP-TTM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The collaboration combines CEVEC's proprietary CAP-TTM expression system with CCS' expertise to produce and process bulk quantities of transiently transfected cells for drug discovery research in pharmaceutical companies worldwide.
"CCS Cell Culture Services is a very experienced and trusted partner for the custom supply of cell based assay reagents. We're very pleased that they will add our CAP-T cells to their cell based assay technology portfolio and we're convinced that the cells will contribute significantly to the drug discovery process in the pharma industry " stated Wolfgang Kintzel, CEO at CEVEC.
Oliver Wehmeier, Managing Director of Cell Culture Services said: "We are excited about the potential of CEVEC's CAP-T technology. The cells meet all requirements for a host cell line in terms of robustness, transfection efficacy, expression level, and scalability. We obtained outstanding results from transient transfections of various secreted, intracellular, or membrane bound target proteins in CAP-T cells and we are pretty sure that this expression system will be of great benefit to our customers"


About CEVEC Pharmaceuticals GmbH


CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-TTM expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Cell Culture Service GmbH


For more than thirteen years, CCS has been supporting research departments of pharmaceutical and biotechnology companies with custom made functionally validated cell based reagents. CCS is one of the leading suppliers of recombinant cell lines, assay-ready frozen cells, qualified membranes, and proteins for high-throughput screening. Major pharmaceutical companies all over Europe and the USA rely on the custom products and services of CCS.

Contacts:


Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com


Dr. Oliver Wehmeier
Managing Director
CCS Cell Culture Service GmbH
Falkenried 88
20251 Hamburg, Germany
fon +49 (0)40 47196560
fax: +49 (0)40 471 965 66
info@CellCultureService.com
 

Cevec raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners

Cologne, Germany, 24 October 2012 – CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund. Additional financing was provided by Midas Group and existing investors Creathor Venture and NRW.Bank. The funds will be used to advance proprietary product developments in the areas of therapeutic proteins and the novel vaccine business of CEVEC.

Köln, 24.October 2012 – Die CEVEC Pharmaceuticals GmbH (CEVEC), ein Entwickler von neuen Expressionssystemen auf Basis menschlicher Zellen zur Produktion von komplexen Biopharmazeutika und Impfstoffen, hat heute den Abschluss ihrer neuen Finanzierungsrunde in Höhe von € 2,8 Mio. unter der Führung des von Peppermint VenturePartners (PVP) gemanagten Charité Biomedical Fund mitgeteilt. Weitere Investoren sind die Midas Gruppe, sowie die bestehenden Investoren Creathor Venture und NRW.Bank. Die eingeworbenen Mittel sollen zum Ausbau eigner Produktentwicklungen bei CEVEC in den Bereichen therapeutische Proteine und Impfstoffe eingesetzt werden.
 

Contact:
Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com